{"entity":{"id":"nct05722418","kind":"trial","name":"CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1 trial of CB-011 run by Caribou Biosciences, Inc., now recruiting.","summary":"CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05722418 by Caribou Biosciences, Inc., with 50 participants planned, started 2023-02-06. Conditions recorded: Relapsed/Refractory Multiple Myeloma. Interventions recorded: CB-011.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05722418","url":"https://clinicaltrials.gov/study/NCT05722418"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["cb-011"],"companies":["caribou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05722418","phase":"1","setting":"A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)","sponsor":"Caribou Biosciences, Inc.","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05722418/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"cb-011","kind":"drug","name":"CB-011","route":"/drugs/cb-011/"}],"company":[{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/"}]}}